Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Antje Jahn-Eimermacher"'
Publikováno v:
BMC Medical Research Methodology, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Random Forests are a powerful and frequently applied Machine Learning tool. The permutation variable importance (VIMP) has been proposed to improve the explainability of such a pure prediction model. It describes the expected increase in pre
Externí odkaz:
https://doaj.org/article/ca698fd2990b42069dba81ae97b1a9ca
Publikováno v:
BMC Medical Research Methodology, Vol 17, Iss 1, Pp 1-13 (2017)
Abstract Background Composite endpoints comprising hospital admissions and death are the primary outcome in many cardiovascular clinical trials. For statistical analysis, a Cox proportional hazards model for the time to first event is commonly applie
Externí odkaz:
https://doaj.org/article/388357f8bd014515baee0bc81ada2e2f
Autor:
Jens Kamuf, Andreas Garcia-Bardon, Bastian Duenges, Tanghua Liu, Antje Jahn-Eimermacher, Florian Heid, Matthias David, Erik K. Hartmann
Publikováno v:
Respiratory Research, Vol 18, Iss 1, Pp 1-9 (2017)
Abstract Background In acute respiratory respiratory distress syndrome (ARDS) a sustained mismatch of alveolar ventilation and perfusion (VA/Q) impairs the pulmonary gas exchange. Measurement of endexpiratory lung volume (EELV) by multiple breath-nit
Externí odkaz:
https://doaj.org/article/3331d86ff0d44709b8cebe690fdc0793
Autor:
Eva-Verena Schaible, Arne Steinsträßer, Antje Jahn-Eimermacher, Clara Luh, Anne Sebastiani, Frida Kornes, Dana Pieter, Michael K Schäfer, Kristin Engelhard, Serge C Thal
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e71056 (2013)
Following traumatic brain injury (TBI) neuroinflammatory processes promote neuronal cell loss. Alpha-melanocyte-stimulating hormone (α-MSH) is a neuropeptide with immunomodulatory properties, which may offer neuroprotection. Due to short half-life a
Externí odkaz:
https://doaj.org/article/d0bdcef54b31416a9e20fe992e07f880
Autor:
Julia Sturm, Heiko Milera, Stephanie Essmann, Anja Fruth, Antje Jahn-Eimermacher, Mareike Selig, Jennifer Winter, Larissa Seidmann, Christoph Kampmann, André Kidszun, Eva Mildenberger, Catharina Whybra
Publikováno v:
Journal of Perinatal Medicine. 50:985-992
Objectives The prognosis of nonimmune hydrops fetalis (NIHF) is still poor with a high mortality and morbidity rate despite progress in perinatal care. This study was designed to investigate etiology and outcome of NIHF. Methods A retrospective revie
Autor:
Anna Dionysopoulou, Etienne Pirih, Doris Macchiella, Anja Fruth, Antje Jahn-Eimermacher, Christoff Kampmann, Eva Mildenberger, Catharina Whybra
Publikováno v:
Reproductive Sciences.
The purpose of this paper is to explore whether the cardiovascular profile score (CVPS) correlates with fetal outcome in patients with non-immune hydrops fetalis (NIHF) and cardiac anomalies. In this retrospective study, we included fetuses with NIHF
Publikováno v:
Statistics in Biopharmaceutical Research. 15:257-267
Publikováno v:
65th Annual Meeting of the German Association for Medical Informatics, Biometry and Epidemiology (GMDS), Meeting of the Central European Network (CEN: German Region, Austro-Swiss Region and Polish Region) of the International Biometric Society (IBS); 20200906-20200909; Berlin; DOCAbstr. 134 /20210226/
Background: Progression-free survival (PFS) is a frequently used endpoint in oncological clinical studies. In case of PFS, potential events are progression and death. Progressions are usually observed delayed as they can be diagnosed not before the n
Autor:
Antje Jahn-Eimermacher, Gerrit Toenges
Publikováno v:
Biometrical Journal. Biometrische Zeitschrift
This work is motivated by clinical trials in chronic heart failure disease, where treatment has effects both on morbidity (assessed as recurrent non‐fatal hospitalisations) and on mortality (assessed as cardiovascular death, CV death). Recently, a
Publikováno v:
65th Annual Meeting of the German Association for Medical Informatics, Biometry and Epidemiology (GMDS), Meeting of the Central European Network (CEN: German Region, Austro-Swiss Region and Polish Region) of the International Biometric Society (IBS); 20200906-20200909; Berlin; DOCAbstr. 95 /20210226/
In heart failure trials efficacy is usually proven by a composite endpoint including cardiovascular death (CVD) and recurrent heart failure hospitalisations (HFH), evaluated with time-to-first-event analysis based on a Cox model. As a considerable fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a01971b98486235664589278cafb417